title: B-cell lymphomas with coexpression of CD5 and CD10.
abstract: Coexpression of CD5 and CD10 is highly unusual in B-cell lymphomas and may pose a diagnostic challenge. We report 42 cases of B-cell lymphoma with simultaneous expression of CD5 and CD10. They made up approximately 0.4% of all B-cell lymphomas seen during the study period and included the following cases: large B-cell lymphoma (LBCL), 14 (33%); follicular lymphoma (FL), 10 (24%); mantle cell lymphoma (MCL), 9 (21%); chronic lymphocytic leukemia, 4 (10%); acute precursor B-cell lymphoblastic leukemia/lymphoma, 2 (5%); and other low-grade B-cell lymphomas, 3 (7%). All MCLs had overexpression of bcl-1 or the t(11;14) and were CD43+. All FLs had typical histomorphologic features and were bcl-2+ and bcl-6+ but CD43-. Of 14 LBCLs, 5 were histologically high-grade. Six (43%) of 14 patients with LBCL died within 10 months of diagnosis of CD5+CD10+ lymphoma (median survival, 4 months), including all 3 patients with stage IV disease and 2 of 5 with histologically high-grade lymphoma. Our findings indicate that coexpression of CD5 and CD10 is rare but occurs in diverse subtypes of B-cell lymphoma. Investigation of bcl-1, bcl-6, and CD43 and morphologic evaluation may resolve the potential confusion in diagnosis and lead to the recognition of the correct lymphoma subtype.
authors.affiliation: IMPATH Inc, 521W 57th St, 6th Floor, New York, NY 10019, USA.
authors.forename: Henry Y
authors.initials: HY
authors.lastname: Dong
authors.forename: Wojciech
authors.initials: W
authors.lastname: Gorczyca
authors.forename: Zach
authors.initials: Z
authors.lastname: Liu
authors.forename: Patricia
authors.initials: P
authors.lastname: Tsang
authors.forename: C Daniel
authors.initials: CD
authors.lastname: Wu
authors.forename: Patti
authors.initials: P
authors.lastname: Cohen
authors.forename: James
authors.initials: J
authors.lastname: Weisberger
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015703:Antigens, CD; D014408:Biomarkers, Tumor / Q000378:metabolism; D018956:CD5 Antigens / Q000378:metabolism*; D019938:Cyclin D1 / Q000378:metabolism; D004268:DNA-Binding Proteins / Q000378:metabolism; D005260:Female; D005434:Flow Cytometry; D019084:Fluorescent Antibody Technique, Indirect; D006801:Humans; D007150:Immunohistochemistry; D016130:Immunophenotyping; D017404:In Situ Hybridization, Fluorescence; D051917:Leukosialin; D016393:Lymphoma, B-Cell / Q000145:classification / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D015260:Neprilysin / Q000378:metabolism*; D011518:Proto-Oncogene Proteins / Q000378:metabolism; D051560:Proto-Oncogene Proteins c-bcl-6; D012795:Sialoglycoproteins / Q000378:metabolism; D014157:Transcription Factors / Q000378:metabolism
chemical_list: D015703:Antigens, CD; D014408:Biomarkers, Tumor; D018956:CD5 Antigens; D004268:DNA-Binding Proteins; D051917:Leukosialin; D011518:Proto-Oncogene Proteins; D051560:Proto-Oncogene Proteins c-bcl-6; C465014:SPN protein, human; D012795:Sialoglycoproteins; D014157:Transcription Factors; D019938:Cyclin D1; D015260:Neprilysin